$5.45 Million in Sales Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter
Wall Street analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce sales of $5.45 million for the current quarter, Zacks reports. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The highest sales estimate is $10.60 million and the lowest is $500,000.00. Arrowhead Pharmaceuticals posted sales of $8.71 million during the same quarter last year, which suggests a negative year-over-year growth rate of 37.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, December 11th.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $12.17 million for the current financial year, with estimates ranging from $5.40 million to $16.00 million. For the next financial year, analysts expect that the business will post sales of $35.10 million per share, with estimates ranging from $200,000.00 to $109.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.62 million.
Shares of ARWR traded up $0.05 on Tuesday, hitting $14.38. 110,905 shares of the stock traded hands, compared to its average volume of 1,836,468. The company has a market capitalization of $1.49 billion, a P/E ratio of -30.38 and a beta of 1.85. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals has a one year low of $1.90 and a one year high of $17.50.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the completion of the sale, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.60% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. RTW Investments LP grew its position in Arrowhead Pharmaceuticals by 184.6% in the 2nd quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after purchasing an additional 5,382,981 shares during the period. OppenheimerFunds Inc. grew its position in Arrowhead Pharmaceuticals by 23.9% in the 1st quarter. OppenheimerFunds Inc. now owns 7,807,644 shares of the biotechnology company’s stock worth $56,293,000 after purchasing an additional 1,507,644 shares during the period. BlackRock Inc. grew its position in Arrowhead Pharmaceuticals by 108.1% in the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after purchasing an additional 3,679,986 shares during the period. Acuta Capital Partners LLC bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $12,706,000. Finally, Nexthera Capital LP bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $8,033,000. 47.20% of the stock is owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Story: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.